NHMRC Glaucoma Guidelines - ANZGIG
NHMRC Glaucoma Guidelines - ANZGIG
NHMRC Glaucoma Guidelines - ANZGIG
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>NHMRC</strong> GUIDELINES FOR THE SCREENING, PROGNOSIS, DIAGNOSIS, MANAGEMENT AND PREVENTION OF GLAUCOMA<br />
Chapter 10 – Laser therapy and surgery<br />
above angle narrowing factors. It is often safer to remove the lens first and in these situations the<br />
angle usually opens further, with a concomitant reduction in IOP. Should the IOP not be reduced<br />
sufficiently, then trabeculectomy can be safely performed.<br />
In subjects with open angle glaucoma and coexistent cataract requiring trabeculectomy, the<br />
consensus is that the cataract should be removed first, when the optic nerve is not severely<br />
damaged. In patients with POAG and without prior surgery, approximately 50% will gain a useful<br />
reduction in IOP from cataract surgery alone, although this reduction tends to be short-lived<br />
(in the order of six months). Should trabeculectomy be required, it can be performed more<br />
safely several months later, without risk of inducing cataract. The difficult cases are those with<br />
severe glaucoma and cataract, where it is often necessary to perform combined cataract and<br />
trabeculectomy surgery to reduce the risk of a pressure spike.<br />
Evidence Statement<br />
Evidence supports using cataract surgery to open the angle in most patients with primary angle closure,<br />
when laser procedures have been inadequate. This is believed to improve the safety of subsequent<br />
drainage surgery.<br />
Point of note<br />
Cataract surgery in patients with advanced glaucoma can lead to loss of remaining vision and/or bleb<br />
failure in eyes which have undergone prior trabeculectomy.<br />
Therapeutic indications for laser therapy and or surgery<br />
Laser therapy is considered in patients who fail to maintain IOP within the specified target range,<br />
and who are resistant to other forms of treatment (AOA 2002). Emerging evidence suggests that<br />
laser therapy is a strategy for IOP reduction that needs to be considered at different stages of<br />
the management spectrum for individual patients, considering its benefits and drawbacks on a<br />
one-by-one basis (see Table 10.1). This guideline provides recommendations regarding first,<br />
second and third choice treatments. For the role of medication and the indications to change<br />
treatment, refer to Chapter 9.<br />
152 National Health and Medical Research Council